International efforts are rewarded with a first order on the Spanish-
market for $630,000
MONTREAL, June 19 /CNW Telbec/ - Ranaz Corporation (TSXV : RNZ) ("Ranaz"
or "the Corporation"), a firm specializing in the manufacturing and marketing
of protein and dietary supplements related to treatment of excess weight and
obesity, announced today an order worth 450,000 euros (about CDN$630,000) for
its products by PronoKal. This customer, based in Spain, is active in several
European countries. The products are deliverable in full in the third quarter
of this year.
This agreement, Ranaz's first major order in Spain, flows directly from
the Corporation's international development plan, with the aim of distributing
its products in foreign markets. Ranaz participates in many international
trade shows and holds numerous meetings with doctors specializing in the
treatment of obesity. This first order with PronoKal is the culmination of its
efforts and the prelude to growth in Europe.
"This agreement represents an interesting geographic breakthrough for
Ranaz and brings us closer to our objective of establishing the Corporation as
a world-class firm in its niche - the manufacturing and marketing of protein
and dietary supplements related to the treatment of excess weight and
obesity," said Jean Bourassa-Marineau, President and Chief Executive Officer
of Ranaz. "We will continue our efforts to extend our distribution network
worldwide, because obesity today is a pandemic social problem. According to
the World Health Organization (WHO), 2 billion adults are overweight or suffer
from obesity around the world."
PronoKal, a company specializing in weight loss, is well established in
Spain with its medically supervised weight loss clinics. Ranaz's products are
already available in Europe in about 800 pharmacies and parapharmacies in
France and Belgium. Under this new agreement, the Corporation's products will
be offered in PronoKal's weight loss and obesity treatment clinics in Spain,
thus sustaining Ranaz's expansion on the European continent.
About Ranaz Corporation
Ranaz is a corporation specializing in manufacturing and marketing
protein and dietary supplements for weight loss and obesity treatment. Its
mission is to design, develop and market nutritional, protein and dietary
supplements under private brands, as well as under its own corporate brands
and concepts, such as Protidiet and ProtiLife. Ranaz shares have traded under
the symbol RNZ on the TSX Venture Exchange since December 29, 2006.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Ranaz's control.
Such risks include but are not limited to: the impact of general economic
conditions, changes in the regulatory environment in the jurisdictions in
which Ranaz does business, stock markets volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation, as well as
other risks disclosed in public filings of Ranaz. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Ranaz is under no obligation and
disavows any intention to update or revise such statements as a result of any
event, circumstances or otherwise.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Martin Vidal, Executive Vice President, Ranaz
Corporation, (450) 491-7106 Ext. 213, email@example.com